Phase I trial of r viscumin (INN: aviscumine) given subcutaneously in patients with advanced cancer: A study of the European Organisation for Research and Treatment of Cancer (EORTC protocol number 13001)

European Journal of Cancer

Volumn 44, Issue 12, 2008, Pages 1657-1662

  Bergmann, Lothar ^a   Aamdal, Steiner ^b   Marreaud, Sandrine ^c   Lacombe, Denis ^c   Herold, Manfred ^d   Yamaguchi, Takuhiro ^c   Wilhelm Ogunbiyi, Karin ^e   Lentzen, Hans ^f   Zwierzina, Heinz ^d  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c EORTC DATA CENTER   (Belgium)

^d INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^e PAION Deutschland GmbH   (Germany)

^f CYTAVIS BioPharma GmbH   (Germany)

Author keywords

Aviscumine; Phase I trial; Ribosome inactivating protein; rViscumin; Solid tumours

Indexed keywords

ANTINEOPLASTIC AGENT; AVISCUMINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; RIBOSOME INACTIVATING PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CHILL; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FEVER; FLUSHING; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; IMMUNOMODULATION; INJECTION SITE REACTION; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SIDE EFFECT; SOFT TISSUE SARCOMA; THORAX PAIN; TREATMENT OUTCOME; VOMITING;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADULT; AGED; ANTIBODIES, NEOPLASM; ANTINEOPLASTIC AGENTS, PHYTOGENIC; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PLANT PREPARATIONS; RIBOSOME INACTIVATING PROTEINS, TYPE 2; TOXINS, BIOLOGICAL; TREATMENT OUTCOME;

EID: 48349135582     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.05.005     Document Type: Article

References (20)

1. Langer M., Möckel B., Eck J., Zinke H., and Lentzen H. Site-specific mutagenesis of mistletoe lectin: the role of RIP activity in apoptosis. Biochem Biophys Res Commun 264 (1999) 944-948
2. Endo Y., Tsurugi K., and Franz H. The site of action of the A-chain of mistletoe lectin I on eukaryotic ribosomes The RNA N-glycosidase activity of the protein. FEBS Lett 231 (1988) 378-380
3. Eck J., Langer M., Möckel B., et al. Cloning of the mistletoe lectin gene and characterization of the recombinant A-chain. Eur J Biochem 264 (1999) 775-784
4. Eck J., Langer M., Möckel B., Witthohn K., Zinke H., and Lentzen H. Characterization of recombinant and plant-derived mistletoe lectin and their B-chains. Eur J Biochem 265 (1999) 788-797
5. Hajto T., Hostanska K., Weber K., et al. Effect of recombinant lectin Viscum album agglutinin on the secretion of interleukin-12 in cultured human peripheral blood mononuclear cells and on NK-cell-mediated cytotoxicity of rat splenocytes in-vitro and in-vivo. Nat Immun 16 (1998) 34-46
6. Schumacher U., Feldhaus S., and Mengs U. Recombinant mistletoe lectin (rML) is successful in treating human ovarian cancer cells transplanted into severe combined immunodeficient (SCID) mice. Cancer Lett 150 (2000) 171-175
7. Schaffrath B., Mengs U., Schwarz T., et al. Anticancer activity of rViscumin (recombinant mistletoe lectin) in tumour colonization models with immunocompetent mice. Anticancer Res 21 (2001) 3981-3988
8. Hostanska K., Vuong V., Rocha S., et al. Recombinant mistletoe lectin induces p53-independent apoptosis in tumour cells and cooperates with ionising radiation. Br J Cancer 88 (2003) 1785-1792
9. Elsässer-Beile U., Ruhnau T., Freudenberg N., Wetterauer U., and Mengs U. Antitumoral effect of recombinant mistletoe lectin on chemically induced urinary bladder carcinogenesis in a rat model. Cancer Lett 91 (2001) 998-1004
10. Müthing J., Burg M., Möckel B., et al. Preferential binding of the anticancer drug rViscumin (recombinant mistletoe lectin) to terminally α2-6-sialylated gangliosides. Glycobiology 12 (2002) 485-497
11. Müthing J., Meisen I., Bulau P., et al. Mistletoe lecting I is a sialic acid-specific lectin with strict preference to gangliosides with terminal neu5 Acα2-6Galβ1-4GlcNAc residues. Biochemistry 43 (2004) 2996-3007
12. Zimring J.C., Levery S.B., Kniep B., et al. CD75s is a marker of murine CD8+ suppressor cells. Int Immunol 15 (2003) 1389-1399
13. Schwarz T., Joller P.W., Möckel B., Weyhenmeyer R., Lentzen H., et al. Recombinant lectin rML: a novel inducer of cytokines in vitro. Eur J Cancer 33 Suppl. 5 (1997) S16
14. Hostanska K., Hajto T., Fischer J., et al. Selective modulation of phosphatidylserine exposure on subpopulations of human peripheral blood lymphocytes by a plant lectin, Viscum album agglutinin (VAA)-I and its recombinant form (rVAA) in vitro. Cancer Detect Prev 23 (1999) 511-523
15. Burger A.M., Mengs U., Schüler J.B., Zinke H., Lentzen H., and Fiebig H.H. Recombinant mistletoe lectin (rML) is a potent inhibitor of tumor cell growth in vitro and in vivo. Proc Am Assoc Cancer Res 40 (1999) 2639
16. Schöffski P., Riggert S., Fumoleau P., et al. Phase I trial of aviscumine (rViscumin) in patients with solid tumours: a study of the European Organisation of Research and Treatment of Cancer New Drug Development Group. Ann Oncol 15 (2004) 1816-1824
17. Schöffski P., Breidenbach I., Krauter J., et al. Weekly 24 h infusion of aviscumine (rViscumin): a phase I study in patients with solid tumours. Eur J Cancer 41 (2005) 1431-1438
18. Adler M., Langer M., Witthohn K., Eck J., Blohm D., and Niemeyer C.M. Detection of rViscumin in plasma samples by immuno-PCR. Biochem Biophys Res Commun 300 (2003) 757-763
19. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-206
20. Möckel B., Schwarz T., Eck J., Langer M., Zinke H., and Lentzen H. Apoptosis and cytokine release are biological responses mediated by recombinant mistletoe lectin in vitro. Eur J.Cancer 33 Suppl. 5 (1997) S35